Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Cynthia J Musante"'
Autor:
Jangir Selimkhanov, W Clayton Thompson, Terrell A Patterson, John R Hadcock, Dennis O Scott, Tristan S Maurer, Cynthia J Musante
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0155674 (2016)
The purpose of this work is to develop a mathematical model of energy balance and body weight regulation that can predict species-specific response to common pre-clinical interventions. To this end, we evaluate the ability of a previously published m
Externí odkaz:
https://doaj.org/article/b8265b1953804725b8d28146b34ee9e1
Autor:
Stephan Schmidt, Valvanera Vozmediano, Rodrigo Cristofoletti, Sarah Kim, Zhoumeng Lin, Natalia deMoraes, Francine Azeredo, Brian Cicali, Hans Leuenberger, Joshua D. Brown, Jin Y. Jin, Cynthia J. Musante, Stacey Tannenbaum, Yaning Wang
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 7, Pp 883-888 (2023)
Externí odkaz:
https://doaj.org/article/08e38ed6155a4e7699df9db375561cb2
Publikováno v:
npj Systems Biology and Applications, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract A quantitative systems pharmacology (QSP) model of the pathogenesis and treatment of SARS-CoV-2 infection can streamline and accelerate the development of novel medicines to treat COVID-19. Simulation of clinical trials allows in silico expl
Externí odkaz:
https://doaj.org/article/e8be75a8806246b68221a90a77af2870
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
The specific pathways, timescales, and dynamics driving the progression of fibrosis in NAFLD and NASH are not yet fully understood. Hence, a mechanistic model of the pathogenesis and treatment of fibrosis in NASH will necessarily have significant unc
Externí odkaz:
https://doaj.org/article/3051fb48e64a4ea79bba6d0b8696a938
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
While anti-PD-1 and anti-PD-L1 [anti-PD-(L)1] monotherapies are effective treatments for many types of cancer, high variability in patient responses is observed in clinical trials. Understanding the sources of response variability can help prospectiv
Externí odkaz:
https://doaj.org/article/4ec46becd7ef40a88b364c8e6689934a
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Non-alcoholic fatty liver disease is a metabolic and inflammatory disease that afflicts many people worldwide and presently has few treatment options. To enhance the preclinical to clinical translation and the design of early clinical trials for nove
Externí odkaz:
https://doaj.org/article/e55ec902b7004652bdc06feba71eb777
Autor:
Daryl J. Fediuk, Gianluca Nucci, Vikas K. Dawra, Ernesto Callegari, Susan Zhou, Cynthia J. Musante, Yali Liang, Kevin Sweeney, Vaishali Sahasrabudhe
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 6, Pp 529-542 (2021)
Abstract Model‐informed drug development (MIDD) is critical in all stages of the drug‐development process and almost all regulatory submissions for new agents incorporate some form of modeling and simulation. This review describes the MIDD approa
Externí odkaz:
https://doaj.org/article/623a24d4e7134b48bea0371f3fb566f6
Publikováno v:
Mathematical Biosciences and Engineering, Vol 16, Iss 3, Pp 1082-1114 (2019)
Non-alcoholic fatty liver disease is the most common cause of chronic liver disease. Precipitated by the build up of extra fat in the liver not caused by alcohol, it is still not understood why steatosis occurs where it does in the liver microstructu
Externí odkaz:
https://doaj.org/article/cf0b2f31863e4fe880283d4a3adc1567
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 5, Pp 393-394 (2021)
Externí odkaz:
https://doaj.org/article/a4dad02ef6cc4c0ea28be6327641d1fa
Autor:
Ernesto Callegari, Kevin Sweeney, Cynthia J. Musante, Susan Zhou, Vaishali Sahasrabudhe, Daryl J. Fediuk, Gianluca Nucci, Vikas Kumar Dawra, Yali Liang
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 6, Pp 529-542 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
Model‐informed drug development (MIDD) is critical in all stages of the drug‐development process and almost all regulatory submissions for new agents incorporate some form of modeling and simulation. This review describes the MIDD approaches used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4f75123d65cb8bcee793bb85a5c8dfa
https://doi.org/10.1002/psp4.12633
https://doi.org/10.1002/psp4.12633